Clinical trial
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma
NCT05695508 is registered in ClinicalTrials.gov with University of Heidelberg Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma
- Lead sponsor
- University of Heidelberg Medical Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 1, 2022
- Completion date
- September 15, 2029
- Enrollment
- 160 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.